Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Raw Materials (2023 - 2025)

Tg Therapeutics (TGTX) has 3 years of Raw Materials data on record, last reported at $4.1 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 134.08% year-over-year to $4.1 million; the TTM value through Sep 2025 reached $4.1 million, up 134.08%, while the annual FY2024 figure was $28.2 million, 327.7% up from the prior year.
  • Raw Materials reached $4.1 million in Q3 2025 per TGTX's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $28.2 million in Q4 2024 and bottomed at $24000.0 in Q1 2023.
  • Average Raw Materials over 3 years is $4.9 million, with a median of $1.7 million recorded in 2024.
  • The widest YoY moves for Raw Materials: up 7129.17% in 2024, down 41.21% in 2024.
  • A 3-year view of Raw Materials shows it stood at $6.6 million in 2023, then soared by 327.7% to $28.2 million in 2024, then plummeted by 85.58% to $4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $4.1 million in Q3 2025, $4.1 million in Q2 2025, and $4.1 million in Q1 2025.